Cholinesterase Inhibitors Market size is expected to cross USD 180 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period, i.e., 2024-2036. In the year 2023, the industry of cholinesterase inhibitors was USD 20 Billion. The market growth is wheeled majorly by the growing prevalence of and hike in frequency rate of dementia caused because of Alzheimer’s and Parkinson’s diseases all over the world. Recently, more than 55 million people have been suffering from dementia globally, over 60% of whom live in low- and middle-income countries, and women are more disproportionately influenced by dementia. Every year, there are nearly 10 million new cases.
The second major factor that is anticipated to drive the growth of the cholinesterase inhibitors market in the forecast period is the prevalence of LATE disease in elderly people and the increase in the percentage of aged people across the planet. Depending on the newest estimations, the number of people older than 65 years with Alzheimer’s dementia is projected to reach 12.7 million by 2050. For instance, a group of researchers assessed the brains of 6,196 people with an average age at death of 88 years and discovered that almost 40% of them may have got limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE creates symptoms equivalent to Alzheimer’s, comprising issues with thinking, reminding, and reasoning, but has other inherent causes involving abnormal clusters of a protein called TDP-43. This protein is also included in frontotemporal dementia, but LATE shows a distinctive pattern of brain transformations and tends to impact people over the age of 80. Therefore, this might increase and drive the market expansion of cholinesterase inhibitors as this is the only effective therapy to cure these diseases.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
∼9% |
|
Base Year Market Size (2023) |
~USD 20 Billion |
|
Forecast Year Market Size (2036) |
~USD 180 Billion |
|
Regional Scope |
|
Indication (Alzheimer Disease Caused Dementia, Perkinson Disease Caused Dementia, Schizophrenia, Lewy Body Dementia, Myasthenia Gravis)
The Alzheimer's disease-caused dementia segment in the cholinesterase inhibitors market is projected to have the largest revenue share with a hold of around 30% by the end of 2036. This segment will have a substantial growth in the market due to its prevalence in patients. Almost 60 to 70% of cases of dementia due to Alzheimer's have been noticed in people in the world. Currently, more than 6 million people across different countries of different ages are suffering from Alzheimer's and this number is anticipated to go around 13 million by 2050. In 2020, the healthcare pressure related to the disease was calculated to be almost USD 305 billion. In 2020, the competitive landscape in AD presented drugs like acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor opponents, which are focused on curing the symptoms of the disease. These medications are quietly efficient and mainly off-patent, therefore making a substantial scope for new entrants into the market.
Route of Administration (Oral, Intravenous, Intramuscular, Transdermal Patch)
The intravenous segment is anticipated to predominance the global market at the time of the forecast period. High bio-attainability of drugs through an intravenous route using large volume wearable injections and expensive rate of IV cholinesterase inhibitors are factors that are calculated to contribute to the largest share of the segment. Moreover, intravenous is usually the prescribed route of administration. This is another reason attributed to the hike of the segment.
Our In-Depth Analysis of the Global Market Includes the Following Segments:
|
Indication |
|
|
Route of Administration |
|
|
Distribution Channels |
|
North American Market Forecast
North America is projected to dominate the global cholinesterase inhibitors market during the forecast period with a revenue share of around 33%. High incidence rates of dementia, Alzheimer’s disease, and Parkinson’s disease will drive the market in North America. A calculated 6.7 million Americans age 65 and older are living with Alzheimer's in 2023. Seventy-three percent are aged 75 or older. The number of Americans living with Alzheimer's is increasing and increasing very quickly. It is also anticipated that by 2050, the number of people age 65 and older with Alzheimer’s may develop to an anticipated 12.7 million, barring the growth of medical advances to stop or cure Alzheimer’s disease. North America’s advanced therapy medicinal products are helping patients worldwide and helping the region to hold its position.
APAC Market Statistics
The cholinesterase inhibitors market in the Asia Pacific is projected to grow at a dynamic CAGR by the end of the forecast period. The quick advancement of the market in the Asia Pacific can be attributed to the development of several hospitals and ambulatory surgery centers. The developed infrastructure will help this region to share significant revenue as the more hospitals are formed the more will be the need of cholinesterase inhibitors drugs. In 2021, the number of beds in medical institutions all over the country achieved 9.4 million, involving 7.4 million in hospitals, 1.7 million in township-level health places, and 0.3 million in public health colleges. Other than that, there are a total of 67,153 ICU beds across all of China. As an outcome, the country has created a unified healthcare system of high quality and efficacy and modified the attainability and approachability of medical resources like cholinesterase inhibitors.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?